New perspectives in the renin-angiotensin-aldosterone system (RAAS) II: albumin suppresses angiotensin converting enzyme (ACE) activity in human.
About 8% of the adult population is taking angiotensin-converting enzyme (ACE) inhibitors to treat cardiovascular disease including hypertension, myocardial infarction and heart failure. These drugs decrease mortality by up to one-fifth in these patients. We and others have reported previously that...
Guardado en:
Autores principales: | Miklós Fagyas, Katalin Úri, Ivetta M Siket, Gábor Á Fülöp, Viktória Csató, Andrea Daragó, Judit Boczán, Emese Bányai, István Elek Szentkirályi, Tamás Miklós Maros, Tamás Szerafin, István Édes, Zoltán Papp, Attila Tóth |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/78a9276d4d164f108c0af1165f2aca3a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
New perspectives in the renin-angiotensin-aldosterone system (RAAS) I: endogenous angiotensin converting enzyme (ACE) inhibition.
por: Miklós Fagyas, et al.
Publicado: (2014) -
Why the renin–angiotensin–aldosterone system (RAAS) in critically ill patients can no longer be ignored
por: Alexander Zarbock, et al.
Publicado: (2021) -
The Renin–Angiotensin–Aldosterone System and Coronavirus Disease 2019
por: Eliecer Coto, et al.
Publicado: (2021) -
Editorial: New Trends in the Renin-Angiotensin-Aldosterone System in Cardiovascular Disease
por: Ewa Szczepanska-Sadowska, et al.
Publicado: (2021) -
COVID-19 pathophysiology may be driven by an imbalance in the renin-angiotensin-aldosterone system
por: Susanne Rysz, et al.
Publicado: (2021)